Neurological impairment in experimental antiphospholipid syndrome is associated with increased ligand binding to hippocampal and cortical serotonergic 5-HT1A receptors

Immunobiology

Volumn 218, Issue 4, 2013, Pages 517-526

  Frauenknecht, Katrin ^a   Katzav, Aviva ^b   Grimm, Christina ^a   Chapman, Joab ^b   Sommer, Clemens J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

5 HT1A receptor; Antiphospholipid antibodies; Antiphospholipid syndrome; Neurotransmitter receptor; Receptor binding densities

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; AMPA RECEPTOR; CD3 ANTIBODY; CD4 ANTIBODY; CD68 ANTIGEN; CD8 ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER RECEPTOR; SEROTONIN 1A RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ASTROCYTE; AUTORADIOGRAPHY; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GLIA CELL; HEMISPHERE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIGAND BINDING; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; MICROGLIA; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PRIMARY SOMATOSENSORY CORTEX; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR UPREGULATION;

ANIMALS; ANTIGENS, DIFFERENTIATION; ANTIPHOSPHOLIPID SYNDROME; ASTROCYTES; AUTOANTIBODIES; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; LYMPHOCYTES; MACROPHAGES; MICE; NERVOUS SYSTEM DISEASES; RECEPTOR, SEROTONIN, 5-HT1A; SOMATOSENSORY CORTEX; UP-REGULATION;

EID: 84875264288     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.06.011     Document Type: Article

References (79)

1. Andreassi C., Zoli A., Riccio A., Scuderi F., Lombardi L., Altomonte L., Eboli M.L. Anticardiolipin antibodies in patients with primary antiphospholipid syndrome: a correlation between IgG titre and antibody-induced cell dysfunctions in neuronal cell cultures. Clin. Rheumatol. 2001, 20:314-318.
2. Aronovich R., Gurwitz D., Kloog Y., Chapman J. Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms. Immunobiology 2005, 210:781-788.
3. Asherson R.A., Mercey D., Phillips G., Sheehan N., Gharavi A.E., Harris E.N., Hughes G.R. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann. Rheum. Dis. 1987, 46:605-611.
4. Belcheva I., Belcheva S., Petkov V.V., Hadjiivanova C., Petkov V.D. Behavorial responses to the 5-HT1A receptor antagonist NAN190 injected into rat CA1 hippocampal area. Gen. Pharmacol. 1997, 28:435-441.
5. Bertrand F., Lehmann O., Lazarus C., Jeltsch H., Cassel J.C. Intraseptal infusions of 8-OH-DPAT in the rat impairs water-maze performances: effects on memory or anxiety?. Neurosci. Lett. 2000, 279:45-48.
6. Brey R.L., Abbott R.D., Curb J.D., Sharp D.S., Ross G.W., Stallworth C.L., Kittner S.J. Beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke 2001, 32:1701-1706.
7. Brey R.L., Chapman J., Levine S.R., Ruiz-Irastorza G., Derksen R.H., Khamashta M., Shoenfeld Y. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus 2003, 12:508-513.
8. Carli M., Lazarova M., Tatarczynska E., Samanin R. Stimulation of 5-HT1A receptors in the dorsal hippocampus impairs acquisition and performance of a spatial task in a water maze. Brain Res. 1992, 595:50-56.
9. Caronti B., Calderaro C., Alessandri C., Conti F., Tinghino R., Pini C., Palladini G., Valesini G. Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J. Autoimmun. 1998, 11:425-429.
10. Cervera R., Khamashta M.A., Shoenfeld Y., Camps M.T., Jacobsen S., Kiss E., Zeher M.M., Tincani A., Kontopoulou-Griva I., Galeazzi M., Bellisai F., Meroni P.L., Derksen R.H., de Groot P.G., Gromnica-Ihle E., Baleva M., Mosca M., Bombardieri S., Houssiau F., Gris J.C., Quéré I., Hachulla E., Vasconcelos C., Roch B., Fernández-Nebro A., Piette J.C., Espinosa G., Bucciarelli S., Pisoni C.N., Bertolaccini M.L., Boffa M.C., Hughes G.R., Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies) Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 2009, 68:1428-1432.
11. Chapman J., Abu-Katash M., Inzelberg R., Yust I., Neufeld M.Y., Vardinon N., Treves T.A., Korczyn A.D. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J. Neurol. Sci. 2002, 203-204:81-84.
12. Chapman J., Cohen-Armon M., Sheonfeld Y., Korczyn A.D. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999, 8:127-133.
13. Cimaz R., Meroni P.L., Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus 2006, 15:191-197.
14. Clemens N., Frauenknecht K., Katzav A., Sommer C., von Landenberg P. In vitro effects of APS-IgG fractions and of a human monoclonal antiphospholipid IgG antibody on HUVECs and monocytes - promotion of procoagulant activity and inflammation. Ann. N. Y. Acad. Sci. 2009, 1173:805-813.
15. Cuadrado M.J., Khamashta M.A., Ballesteros A., Godfrey T., Simon M.J., Hughes G.R. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore). 2000, 79:57-68.
16. Dale R.C., Yin K., Ding A., Merheb V., Varadkhar S., McKay D., Singh-Grewal D., Brilot F. Antibody binding to neuronal surface in movement disorders associated with lupus and antiphospholipid antibodies. Dev. Med. Child Neurol. 2011, 53:522-528.
17. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 2001, 7:1189-1193.
18. Diederich K., Quennet V., Bauer H., Müller H.D., Wersching H., Schäbitz W.R., Minnerup J., Sommer C. Successful regeneration after experimental stroke by granulocyte-colony stimulating factor is not further enhanced by constraint-induced movement therapy either in concurrent or in sequential combination therapy. Stroke 2012, 43:185-192.
19. Dringenberg H.C., Hargreaves E.L., Baker G.B., Cooley R.K., Vanderwolf C.H. p-chloro-phenylalanine-induced serotonin depletion: reduction in exploratory locomotion but no obvious sensory-motor deficits. Behav. Brain Res. 1995, 68:229-237.
20. Franklin K.J.B., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 1997, Academic Press Inc., San Diego, CA, USA.
21. Frauenknecht K., Plaschke K., Sommer C. Transient oligemia is associated with long-term changes in binding densities of cortical inhibitory GABAA receptors in the rat brain. Brain Res. 2009, 1271:95-102.
22. Frauenknecht K., Bargiotas P., Bauer H., von Landenberg P., Schwaninger M., Sommer C. Neuroprotective effect of Fn14 deficiency is associated with induction of the granulocyte-colony stimulating factor (G-CSF) pathway in experimental stroke and enhanced by a pathogenic human antiphospholipid antibody. J. Neuroimmunol. 2010, 227:1-9.
23. Gharavi A.E., Vega-Ostertag M., Espinola R.G., Liu X., ColeL, Cox N.T., Romagnoli P., Labat K., Pierangeli S.S. Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies. Lupus 2004, 13:17-23.
24. Gomez-Puerta J.A., Cervera R., Calvo L.M., GomezAnson B., Espinosa G., Claver G. Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. Rheumatology (Oxford) 2005, 44:95-99.
25. Harris E.N., Englert H., Derve G., Hughes G.R., Gharavi A. Antiphospholipid antibodies in acute Guillain-Barre syndrome. Lancet 1983, 2:1361-1362.
26. Hensler J.G., Kovachich G.B., Frazer A. A quantitative autoradiographic study of serotonin1A receptor regulation. Effect of 5,7-dihydroxytryptamine and antidepressant treatments. Neuropsychopharmacology 1991, 4:131-144.
27. Hensler J.G., Ferry R.C., Labow D.M., Kovachich G.B., Frazer A. Quantitative autoradiography of the serotonin transporter to assess the distribution of serotonergic projections from the dorsal raphe nucleus. Synapse 1994, 17:1-15.
28. Holmes A. Mouse behavioral models of anxiety and depression. Mouse Behavioral Phenotyping 2003, 43-47. Society for Neuroscience, Washington, DC. J.N. Crawley (Ed.).
29. Hughes G.R. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br. Med. J. 1983, 287:1088-1089.
30. Hughes G.R. Migraine, memory loss, and "multiple sclerosis." Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad. Med. J. 2003, 79:81-83.
31. Katzav A., Pick C.G., Korczyn A.D., Oest E., Blank M., Shoenfeld Y., Chapman J. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 2001, 10:496-499.
32. Katzav A., Chapman J., Shoenfeld Y. CNS dysfunction in the antiphospholipid syndrome. Lupus 2003, 12:903-907.
33. Katzav A., Litvinjuk Y., Pick C.G., Blank M., Shoenfeld Y., Sirota P., Chapman J. Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome. Behav. Brain Res. 2006, 169:289-293.
34. Katzav A., Shoenfeld Y., Chapman J. The pathogenesis of neural injury in animal models of the antiphospholipid syndrome. Clin. Rev. Allergy Immunol. 2010, 38:196-200.
35. Kent M.N., Alvarez F.J., Ng A.K., Rote N.S. Ultrastructural localization of monoclonal antiphospholipid antibody binding to rat brain. Exp. Neurol. 2000, 163:173-179.
36. Kia H.K., Miquel M.C., Brisorgueil M.J., Daval G., Riad M., El Mestikawy S., Hamon M., Vergé D. Immunocytochemical localization of serotonin1A receptors in the rat central nervous system. J. Comp. Neurol. 1996, 365:289-305.
37. Kowal C., DeGiorgio L.A., Lee J.Y., Edgar M.A., Huerta P.T., Volpe B.T., Diamone B. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:19854-19859.
38. Krause I., Lev S., Fraser A., Blank M., Lorber M., Stojanovich L., Rovensky J., Chapman J., Shoenfeld Y. Close association between valvular disease and central nervous system manifestations in antiphospholipid syndrome. Ann. Rheum. Dis. 2005, 64:1490-1493.
39. Krause I., Leibovici L., Blank M., Shoenfeld Y. Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis. Lupus 2007, 16:176-180.
40. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., Derksen R.H., Groot D.E.P.G., Koike T., Meroni P.L., Reber G., Shoenfeld Y., Tincani A., Vlachoyiannopoulos P.G., Krilis S.A. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006, 2:295-306.
41. Mosek A., Yust I., Treves T.A., Vardinon N., Korczyn A.D., Chapman J. Dementia and atniphospholipid antibodies. Dement. Geriatr. Cogn. Disord. 2000, 11:36-38.
42. Müller H.D., Hanumanthiah K.M., Diederich K., Schwab S., Schäbitz W.R., Sommer C. Brain-derived neurotrophic factor but not forced arm use improves long-term outcome after photothrombotic stroke and transiently upregulates binding densities of excitatory glutamate receptors in the rat brain. Stroke 2008, 39:1012-1021.
43. Muldoon M.F., Mackey R.H., Williams K.V., Korytkowski M.T., Flory J.D., Manuck S.B. Low central nervous system serotonergic responsivity is associated with the metabolic syndrome and physical inactivity. J. Clin. Endocrinol. Metab. 2004, 89:266-271.
44. Nowacki P., Ronin-Walknowska E., Ossowicka-Stepinska J. Neuropathological changes within the brain of rabbits with experimental model of antiphospholipid syndrome in different time after immunization. Folia Neuropathol. 1999, 37:269-272.
45. Nowacki P., Ossowicka-Stepinska J., Ronin-Walkanowska E., Tabaka J. The antiphospholipid syndrome in pregnant rabbits and their offspring. Neuropathological aspects. Folia Neuropathol. 2005, 43:15-22.
46. 1A receptors in learning and memory. Behav. Brain Res. 2008, 195:54-77.
47. Ohno M., Watanabe S. Blockade of 5-HT1A receptors compensates loss of hippocampal cholinergic neurotransmission involved in working memory of rats. Brain Res. 1996, 736:180-188.
48. Olivier B., Pattij T., Wood S.J., Oosting R., Sarnyai Z., Toth M. The 5-HT(1A) receptor knockout mouse and anxiety. Behav. Pharmacol. 2001, 12:439-450.
49. Palacios J.M., Wamsley J.K., Kuhar M.J. High affinity GABA receptors - autoradiographic localization. Brain Res. 1981, 222:285-307.
50. Redecha P., Franzke C.-W., Ruf W., Mackman N., Girardi G. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J. Clin. Invest. 2008, 118:3453-3461.
51. Saidi S., Mahjoub T., Almawi W.Y. Lupus anticoagulants and antiphospholipid antibodies as risk factors for a first episode of ischemic stroke. J. Thromb. Haemost. 2009, 7:1075-1080.
52. Sakai N., Tanaka C. Inhibitory modulation of long-term potentiation via the 5-HT1A receptor in slices of the rat hippocampal dentate gyrus. Brain Res. 1993, 613:326-330.
53. Sakurai S.Y., Cha J.H., Penney J.B., Young A.B. Regional distribution and properties of [3H]MK-801 binding sites determined by quantitative autoradiography in rat brain. Neuroscience 1991, 40:533-543.
54. Sanna G., Bertolaccini M.L., Cuadrado M.J., Laing H., Khamashta M.A., Mathieu A., Hughes G.R. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J. Rheumatol. 2003, 30:985-992.
55. Sanna G., DCruz D., Cuadrado M.J. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum. Dis. Clin. North Am. 2006, 32:465-490.
56. Sastre-Garriga J., Montalban X. APS and the brain. Lupus 2003, 12:877-882.
57. Shoenfeld Y., Nahum A., Korczyn A.D., Dano M., Rabinowitz R., Beilin O., Pick C.G., Leider-Trejo L., Kalashnikova L., Blank M., Chapman J. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003, 12:436-442.
58. Shoenfeld Y., Lev S., Blatt I., Blank M., Font J., von Landenberg P., Lev N., Zaech J., Cervera R., Piette J.C., Khamashta M.A., Bertolaccini M.L., Hughes G.R., Youinou P., Meroni P.L., Pengo V., Alves J.D., Tincani A., Szegedi G., Lakos G., Sturfelt G., Jönsen A., Koike T., Sanmarco M., Ruffatti A., Ulcova-Gallova Z., Praprotnik S., Rozman B., Lorber M., Chapman J., van-Breda-Vriezman P.J., Damoiseaux J. Features associated with epilepsy in the antiphospholipid syndrome. J. Rheumatol. 2004, 31:1344-1348.
59. Shoenfeld Y., Twig G., Katz U., Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J. Autoimmun. 2008, 30:74-83.
60. Shrot S., Katzav A., Korczyn A.D., Litvinjuk Y., Hershenson R., Pick C.G., Blank M., Zaech J., Shoenfeld Y., Sirota P., Chapman J. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 2002, 11:736-743.
61. Standley S., Tocco G., Tourigny M.-F., Massicotte F., Thompson R.F., Baudry M. Developmental changes in α-amino-3-hydroxy-5-methyl-4-isoxazole proprionate receptor properties and expression in the rat hippocampal formation. Neuroscience 1995, 67:881-892.
62. Tanay E., Mundel P., Sommer C. Short-term ischemia usually used for ischemic preconditioning causes loss of dendritic integrity after long-term survival in the gerbil hippocampus. Brain Res. 2006, 1112:222-226.
63. Tanne D., Hassin-Baer S. Neurologic manifestation of the antiphospholipid syndrome. Curr. Rheumatol. Rep. 2001, 3:286-292.
64. Tanne D., Katzav A., Beilin O., Grigoriadis N.C., Blank M., Pick C.G., Landenberg P., Shoenfeld Y., Chapman J. Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome. Neurobiol. Dis. 2008, 30:56-64.
65. Terry A.V., Buccafusco J.J., Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav. Brain Res. 2008, 195:30-38.
66. Topic B., Willuhn I., Palomero-Gallagher N., Zilles K., Huston J.P., Hasenöhrl R.U. Impaired maze performance in aged rats is accompanied by increased density of NMDA, 5-HT1A, and alpha-adrenoceptor binding in hippocampus. Hippocampus 2007, 17:68-77.
67. üceyler N., Schütt M., Palm F., Vogel C., Meier M., Schmitt A., Lesch K.P., Mössner R., Sommer C. Lack of the serotonin transporter in mice reduces locomotor activity and leads to gender-dependent late onset obesity. Int. J. Obes. (Lond.) 2010, 34:701-711.
68. van Abeelen J.H. Genetics of rearing behavior in mice. Behav. Genet. 1970, 1:71-76.
69. Verge D., Daval G., Marcinkiewicz M., Patey A., el Mestikawy S., Gozlan H., Hamon M. Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J. Neurosci. 1986, 6:3474-3482.
70. Verrot D., San-Marco M., Dravet C., Genton P., Disdier P., Bolla G., Harle J.R., Reynaud L., Weiller P.J. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am. J. Med. 1997, 103:33-37.
71. Walf A.A., Frye C.A. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat. Protoc. 2007, 2:322-328.
72. Weizman R., Paz L., Backer M.M., Amiri Z., Modai I., Pick C.G. Mouse strains differ in their sensitivity to alprazolam effect in the staircase test. Brain Res. 1999, 839:58-65.
73. Weizman R., Paz L., Peter Y., Toren P., Pick C.G. Behavioral effects of agents active at the gamma-aminobutyric acid receptor complex in the staircase paradigm. Brain Res. 2001, 901:137-142.
74. Yasuno F., Suhara T., Nakayama T., Ichimiya T., Okubo Y., Takano A., Ando T., Inoue M., Maeda J., Suzuki K. Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory. Am. J. Psychiatry 2003, 160:334-340.
75. Zhang H.-T., Huang Y., Masood A., Stolinski L.R., Li Y., Zhang L., Dlaboga D., Jin S.L., Conti M., O'Donnell J.M. Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology 2008, 33:1611-1623.
76. Zilles K., Wu J., Crusio W.E., Schwegler H. Water maze and radial maze learning and the density of binding sites of glutamate, GABA, and serotonin receptors in the hippocampus of inbred mouse strains. Hippocampus 2000, 10:213-225.
77. Zilles K., Palomero-Gallagher N., Schleicher A. Transmitter receptors and functional anatomy of the cerebral cortex. J. Anat. 2004, 205:417-432.
78. Ziporen L., Shoenfeld Y., Levy Y., Korczyn A.D. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J. Clin. Invest. 1997, 100:613-619.
79. Ziporen L., Polak-Charcon S., Korczyn D.A., Goldberg I., Afek A., Kopolovic J., Chapman J., Shoenfeld Y. Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model. Clin. Dev. Immunol. 2004, 11:67-75.